Anouk Donners

154 Chapter 8 29. Oladapo AO, Epstein JD, Williams E, Ito D, Gringeri A, Valentino LA. Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials. Haemophilia. 2015; 21: e344-358. 30. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16: 199-208. 31. Fitriana TS, Purba FD, Rahmatika R, Muhaimin R, Sari NM, Bonsel G, Stolk E, Busschbach JJV. Comparing measurement properties of EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients. Health Qual Life Outcomes. 2021; 19: 256. 32. Luijten MAJ, van Litsenburg RRL, Terwee CB, Grootenhuis MA, Haverman L. Psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS(R)) pediatric item bank peer relationships in the Dutch general population. Qual Life Res. 2021; 30: 2061-2070. 33. Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, Bernelot Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA. Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. Rheumatology (Oxford). 2015; 54: 2221-2229. 34. Kuijlaars IAR, Teela L, van Vulpen LFD, Timmer MA, Coppens M, Gouw SC, Peters M, Kruip M, Cnossen MH, Muis JJ, van Hoorn ES, Haverman L, Fischer K. Generic PROMIS item banks in adults with hemophilia for patient-reported outcome assessment: Feasibility, measurement properties, and relevance. Res Pract Thromb Haemost. 2021; 5: e12621. 35. Groen WG, Takken T, van der Net J, Helders PJ, Fischer K. Habitual physical activity in Dutch children and adolescents with haemophilia. Haemophilia. 2011; 17: e906-912. 36. Versloot O, van Balen EC, Hassan S, Schols SEM, Leebeek FWG, Eikenboom J, Coppens M, van Vulpen LFD, Smit C, Driessens MHE, van der Net J, Gouw SC, Fischer K, Haemophilia in the Netherlands 6 steering c. Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. Haemophilia. 2021; 27: 876-885. 37. Hooimeijer HL, Lukens MV, Verhagen MV, Meijer K, Stein-Wit MA, Tamminga RYJ. A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurement. Haemophilia. 2020; 26: e138-e140. 38. Chuansumrit A, Sirachainan N, Jaovisidha S, Jiravichitchai T, Kadegasem P, Kempka K, Panuwannakorn M, Rotchanapanya W, Nuntiyakul T. Effectiveness of monthly low dose emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: A case series report. Haemophilia. 2022; 29: 382-385. 39. Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022; 28: 103-110. 40. Denhoff ER, Milliren CE, de Ferranti SD, Steltz SK, Osganian SK. Factors Associated with Clinical Research Recruitment in a Pediatric Academic Medical Center--A Web-Based Survey. PLoS One. 2015; 10: e0140768.